Growing research from the neurosciences and cognitive sciences reveal that change really is difficult for humans.
FORBES: Why We're So Afraid of Change -- And Why That Holds Businesses Back
Athena Neurosciences was founded as a stand-alone company in 1987 with the express purpose of curing Alzheimer's.
"Progress is continuing to be made to improve services based on the Adult Neurosciences review, " the spokesperson added.
This speculation is based on studies reported last week at the European Federation of Neurosciences Society in Sweden.
FORBES: For Pfizer-JNJ Alzheimer's Drug, It May Be Too Late To Try
From the beginning, in March 1996, with the acquisition of Athena Neurosciences, Elan has been barking up the wrong tree.
FORBES: From Castle to Dungeon - Lessons From Company's Alzheimer's Failure
Selkoe teamed up with venture capitalists in 1986 to found Athena Neurosciences, now part of Elan Corp. of Dublin, Ireland.
Small- and medium-sized companies, as well as big corporations, including Cerner, Garmin, Google, and TEVA Neurosciences, are members.
The Hurstwood Park regional centre for neurosciences will be expanded and relocated.
"We are talking about something much, much, much, much milder than a high, " said Piomelli, a researcher at the Neurosciences Institute of San Diego.
But lately, all of those have seemed to be supporting players to AN-1792, a compound developed by scientists at Elan's Athena Neurosciences unit in San Francisco.
Lieberburg has been developing Alzheimer's medicines at Elan's South San Francisco research labs for a decade and a half, since they were a standalone biotech called Athena Neurosciences .
But lately, those drugs have seemed to be supporting players to AN-1792, a compound developed by scientists at Elan's Athena Neurosciences unit in San Francisco, a unit once headed by Lieberburg.
In Neurosciences from Stanford University.
FORBES: There's More To Fighting Poverty Than Writing Big Checks And Claiming Tax Deductions
Gary Landreth, one of the authors of Thursday's Science paper and a professor of neurosciences at Case Western Reserve University in Cleveland, said he expected to begin a safety study in 12 healthy patients next month, but there weren't any current plans for a larger clinical trial.
Neurologist Samuel Hunter at the Advanced Neurosciences Institute in Franklin, Tennessee, noted in a February 14 article in the Financial Times that there is extensive patient data compiled on Gilenya and that the response of the EMA and Health Canada is likely an overreaction to recent deaths.
应用推荐